Impax Laboratories, Inc. (NASDAQ:IPXL)‘s stock had its “buy” rating restated by analysts at BTIG Research in a research report issued to clients and investors on Saturday. They currently have a $27.00 price objective on the specialty pharmaceutical company’s stock, up from their previous price objective of $20.00. BTIG Research’s price objective would indicate a potential upside of 17.39% from the company’s current price.

Several other brokerages have also recently weighed in on IPXL. Cantor Fitzgerald upped their target price on shares of Impax Laboratories from $20.00 to $25.00 and gave the company an “overweight” rating in a research report on Monday, September 11th. Citigroup Inc. upped their target price on shares of Impax Laboratories to $23.00 and gave the company a “buy” rating in a research report on Tuesday. Deutsche Bank AG reiterated a “buy” rating and set a $23.00 price target on shares of Impax Laboratories in a research note on Tuesday. Piper Jaffray Companies reiterated a “hold” rating and set a $17.00 price target on shares of Impax Laboratories in a research note on Sunday, September 17th. Finally, Canaccord Genuity began coverage on shares of Impax Laboratories in a research note on Monday, July 31st. They set a “hold” rating and a $19.00 price target on the stock. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $19.03.

Impax Laboratories (NASDAQ IPXL) traded down 3.36% during trading on Friday, reaching $23.00. 1,568,934 shares of the company’s stock traded hands. The firm’s market capitalization is $1.65 billion. The company has a 50-day moving average price of $19.12 and a 200 day moving average price of $15.63. Impax Laboratories has a one year low of $7.75 and a one year high of $27.29.

Impax Laboratories (NASDAQ:IPXL) last announced its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.04. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. The company had revenue of $202.08 million for the quarter, compared to analysts’ expectations of $195.62 million. During the same quarter in the previous year, the company posted $0.21 EPS. The firm’s quarterly revenue was up 17.1% on a year-over-year basis. On average, analysts anticipate that Impax Laboratories will post $0.70 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Impax Laboratories, Inc. (IPXL) Stock Rating Reaffirmed by BTIG Research” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/23/impax-laboratories-inc-ipxl-stock-rating-reaffirmed-by-btig-research.html.

Several hedge funds have recently bought and sold shares of the company. Arizona State Retirement System boosted its holdings in shares of Impax Laboratories by 0.3% in the second quarter. Arizona State Retirement System now owns 38,476 shares of the specialty pharmaceutical company’s stock valued at $619,000 after acquiring an additional 100 shares during the period. Seven Bridges Advisors LLC lifted its holdings in shares of Impax Laboratories by 0.3% during the second quarter. Seven Bridges Advisors LLC now owns 32,190 shares of the specialty pharmaceutical company’s stock worth $928,000 after purchasing an additional 108 shares during the period. Boston Advisors LLC lifted its holdings in shares of Impax Laboratories by 1.1% during the second quarter. Boston Advisors LLC now owns 11,785 shares of the specialty pharmaceutical company’s stock worth $340,000 after purchasing an additional 125 shares during the period. State of Alaska Department of Revenue lifted its holdings in shares of Impax Laboratories by 1.9% during the first quarter. State of Alaska Department of Revenue now owns 8,140 shares of the specialty pharmaceutical company’s stock worth $102,000 after purchasing an additional 150 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Impax Laboratories by 1.2% during the first quarter. Massachusetts Financial Services Co. MA now owns 14,414 shares of the specialty pharmaceutical company’s stock worth $182,000 after purchasing an additional 171 shares during the period. 86.26% of the stock is owned by institutional investors and hedge funds.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.